28458935|t|Successful Management of Acquired Hemophilia A Associated with Bullous Pemphigoid: A Case Report and Review of the Literature
28458935|a|Background. Acquired hemophilia A (AHA) is a rare condition, due to the spontaneous formation of neutralizing antibodies against endogenous factor VIII. About half the cases are associated with pregnancy, postpartum, autoimmune diseases, malignancies, or adverse drug reactions. Symptoms include severe and unexpected bleeding that may prove life-threatening. Case Study. We report a case of AHA associated with bullous pemphigoid (BP), a chronic, autoimmune, subepidermal, blistering skin disease. To our knowledge, this is the 25th documented case of such an association. Following treatment for less than 3 months consisting of methylprednisolone at decreasing dose levels along with four courses of rituximab (monoclonal antibody directed against the CD20 protein), AHA was completely cured and BP well-controlled. Conclusions. This report illustrates a rare association of AHA and BP, supporting the possibility of eradicating the inhibitor with a well-conducted short-term treatment.
28458935	0	21	Successful Management	T058	C0376636
28458935	25	33	Acquired	T080	C0439661
28458935	34	46	Hemophilia A	T047	C0019069
28458935	63	81	Bullous Pemphigoid	T047	C0030805
28458935	85	96	Case Report	T170	C0085973
28458935	101	125	Review of the Literature	T170	C0282441
28458935	138	146	Acquired	T080	C0439661
28458935	147	159	hemophilia A	T047	C0019069
28458935	161	164	AHA	T047	C0019069
28458935	171	185	rare condition	T047	C0678236
28458935	198	209	spontaneous	T169	C0205359
28458935	210	219	formation	T169	C1522492
28458935	223	246	neutralizing antibodies	T116,T129	C0475463
28458935	255	277	endogenous factor VIII	T169	C1516853
28458935	294	299	cases	T169	C0868928
28458935	320	329	pregnancy	T040	C0032961
28458935	331	341	postpartum	T079	C0086839
28458935	343	362	autoimmune diseases	T047	C0004364
28458935	364	376	malignancies	T191	C4282132
28458935	381	403	adverse drug reactions	T046	C0041755
28458935	405	413	Symptoms	T184	C1457887
28458935	422	428	severe	T080	C0205082
28458935	444	452	bleeding	T046	C0019080
28458935	468	484	life-threatening	T033	C2826244
28458935	486	496	Case Study	T170	C0085973
28458935	501	507	report	T170	C0684224
28458935	510	514	case	T169	C0868928
28458935	518	521	AHA	T047	C0019069
28458935	538	556	bullous pemphigoid	T047	C0030805
28458935	558	560	BP	T047	C0030805
28458935	565	572	chronic	T079	C0205191
28458935	574	584	autoimmune	T046	C0004368
28458935	586	598	subepidermal	T033	C1856956
28458935	600	623	blistering skin disease	T033	C4314154
28458935	660	670	documented	T058	C1301725
28458935	671	675	case	T169	C0868928
28458935	710	719	treatment	T061	C0087111
28458935	736	742	months	T079	C0439231
28458935	757	775	methylprednisolone	T109,T121,T125	C0025815
28458935	779	789	decreasing	T033	C0442797
28458935	790	794	dose	T081	C0178602
28458935	795	801	levels	T080	C0441889
28458935	818	825	courses	T079	C0750729
28458935	829	838	rituximab	T116,T121,T129	C0393022
28458935	840	859	monoclonal antibody	T116,T129	C0003250
28458935	881	893	CD20 protein	T116,T123	C1447954
28458935	896	899	AHA	T047	C0019069
28458935	915	920	cured	T077	C1880198
28458935	925	927	BP	T047	C0030805
28458935	928	943	well-controlled	T169	C3853142
28458935	963	969	report	T170	C0684224
28458935	1004	1007	AHA	T047	C0019069
28458935	1012	1014	BP	T047	C0030805
28458935	1046	1057	eradicating	T058	C3178994
28458935	1062	1071	inhibitor	T080	C1999216
28458935	1094	1104	short-term	T079	C0443303
28458935	1105	1114	treatment	T061	C0087111